4487-57-4

Basic information

• Product Name: 2,4-DIBROMO-5-NITROPYRIDINE
• Synonyms: 2,4-DIBROMO-5-NITROPYRIDINE;2,4-DibroMo-5-nitropyridine DISCONTINUED;Pyridine,2,4-dibromo-5-nitro-
• CAS NO: 4487-57-4
• Molecular Formula: C₅H₂Br₂N₂O₂
• Molecular Weight: 281.89
• EINECS: 213-580-7
• Product Categories: Pyridine series;Aromatics;Heterocycles;Intermediates;Heterocycle-Pyridine series
• Mol File: 4487-57-4.mol
• Article Data: 10

Chemical Properties

• Melting Point: 99 °C
• Boiling Point: 292 °C at 760 mmHg
• Flash Point: 130.4 °C
• Appearance: /
• Density: 2.221 g/cm³
• Vapor Pressure: 0.0033mmHg at 25°C
• Refractive Index: 1.649
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: -2.18±0.10(Predicted)
• CAS DataBase Reference: 2,4-DIBROMO-5-NITROPYRIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 2,4-DIBROMO-5-NITROPYRIDINE(4487-57-4)
• EPA Substance Registry System: 2,4-DIBROMO-5-NITROPYRIDINE(4487-57-4)

Safety Data

• Hazardous Substances Data: 4487-57-4(Hazardous Substances Data)

Usage

Description

2,4-DIBROMO-5-NITROPYRIDINE is a tri-substituted pyridine derivative characterized by the presence of two bromine atoms at the 2nd and 4th positions and a nitro group at the 5th position on the pyridine ring. This chemical structure endows it with specific properties that make it suitable for various applications in the pharmaceutical and chemical industries.

Uses

Used in Pharmaceutical Industry:
2,4-DIBROMO-5-NITROPYRIDINE is used as a key intermediate compound for the synthesis of AKT kinase inhibitors. These inhibitors play a crucial role in the development of targeted therapies for various cancers by modulating the activity of AKT kinase, which is often overactive in cancer cells, contributing to tumor growth and survival.
2,4-DIBROMO-5-NITROPYRIDINE is also used as a building block in the development of antihypertensive agents. These agents help regulate blood pressure by targeting specific receptors or enzymes involved in the regulation of vascular tone and fluid balance in the body.

InChI:InChI=1/C5H2Br2N2O2/c6-3-1-5(7)8-2-4(3)9(10)11/h1-2H

Upstream product

• 13091-23-1 4-chloro-3-nitropyridine 
• 850663-54-6 4-chloro-2-hydroxy-5-nitropyridine 
• 31872-62-5 4-methoxy-3-nitro-pyridine 
• 607373-82-0 2-hydroxy-4-methoxy-5-nitro pyridine 

Downstream Products

• 1449669-27-5 2-bromo-5-nitro-4-vinylpyridine 
• 1449669-28-6 2-(1-methyl-1H-pyrazol-4-yl)-5-nitro-4-vinylpyridine 
• 1449669-29-7 4-ethyl-6-(1-methyl-1H-pyrazol-4-yl)pyridin-3-ylamine 
• 1449669-30-0 N-(4-ethyl-6-(1-methyl-1H-pyrazol-4-yl)pyridin-3-yl)-1-methyl-1H-imidazo[4,5-c]pyridin-6-amine 
• 1449665-20-6 N-(4-ethyl-6-(1-methyl-1H-pyrazol-4-yl)pyridin-3-yl)-N,1-dimethyl-1H-imidazo[4,5-c]pyridin-6-amine 
• 1612171-82-0 (2-bromo-5-nitropyridin-4-yl)isopropylamine 
• 1612172-37-8 4-[4-(1-isopropyl-1H-imidazo[4,5-c]pyridin-6-ylamino)pyrimidin-2-yl]piperidine-1-carboxylic acid tert-butyl ester 
• 1612172-38-9 4-[4-(1-isopropyl-1H-imidazo[4,5-c]pyridin-6-ylamino)pyrimidin-2-yl]-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester 
• 1612172-39-0 4-[4-(1-isopropyl-1H-imidazo[4,5-c]pyridin-6-ylamino)pyrimidin-2-yl]-1,2,3,6-tetrahydropyridinium chloride 
• 1612164-36-9 (1-isopropyl-1H-imidazo[4,5-c]pyridin-6-yl)-[2-(1-methanesulfonyl-1,2,3,6-tetrahydropyridin-4-yl)pyrimidin-4-yl]amine 
• 1612164-37-0 (1-isopropyl-1H-imidazo[4,5-c]pyridin-6-yl)-(2-morpholin-4-ylpyrimidin-4-yl)amine 
• 1612164-51-8 N⁴-(1-isopropyl-1H-imidazo[4.5-c]pyridin-6-yl)-N²-(1H-pyrazol-4-yl)pyrimidine-2,4-diamine 
• 1612164-52-9 1-isopropyl-N-(2-(4-(trifluoromethoxy)piperidin-1-yl)pyrimidin-4-yl)-1H-imidazo[4,5-c]pyridin-6-amine 
• 1612172-56-1 benzyl N-((1R,5S,6s)-3-(4-((1-isopropyl-1H-imidazo[4,5-c]pyridin-6-yl)amino)pyrimidin-2-yl)-3-azabicyclo[3.1.0]hexan-6-yl)carbamate 

Relevant articles and documents

EGFR PROTEOLYSIS TARGETING CHIMERIC MOLECULES AND ASSOCIATED METHODS OF USE

The present disclosure relates to bifunctional compounds, which find utility as modulators of receptor tyrosine kinase (RTK) proteins. In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a ligand which binds to an E3 ubiquitin ligase and on the other end a moiety which binds a target protein, such that the target protein is placed in proximity to the ubiquitin ligase to effectuate ubiquitination, and therefore, degradation (and inhibition) of the target protein. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aggregation or accumulation of the target protein are treated or prevented with compounds and compositions of the present disclosure.

Structure-based drug design of novel, potent, and selective azabenzimidazoles (ABI) as ATR inhibitors

Compound 13 was discovered through morphing of the ATR biochemical HTS hit 1. The ABI series was potent and selective for ATR. Incorporation of a 6-azaindole afforded a marked increase in cellular potency but was associated with poor PK and hERG ion channel inhibition. DMPK experiments established that CYP P450 and AO metabolism in conjunction with Pgp and BCRP efflux were major causative mechanisms for the observed PK. The series also harbored the CYP3A4 TDI liability driven by the presence of both a morpholine and an indole moiety. Incorporation of an adjacent fluorine or nitrogen into the 6-azaindole addressed many of the various medicinal chemistry issues encountered. (Chemical Presented).

IMIDAZO [4, 5 -C] PYRIDINE DERIVATIVES USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES

Wherein R1, L1, R3, R4, Cy, L2 and R5 are as defined herein. Novel imidazolopyridines according to Formula I, able to inhibit JAK are disclosed, these compounds may be prepared as a pharmaceutical composition, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, allergic or inflammatory conditions, autoimmune diseases, proliferative diseases, transplantation rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of IL6 or interferons.